These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 20130650)

  • 21. The CML stem cell: evolution of the progenitor.
    Stuart SA; Minami Y; Wang JY
    Cell Cycle; 2009 May; 8(9):1338-43. PubMed ID: 19342894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
    Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
    Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.
    Helgason GV; Karvela M; Holyoake TL
    Blood; 2011 Aug; 118(8):2035-43. PubMed ID: 21693757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.
    Kobayashi CI; Takubo K; Kobayashi H; Nakamura-Ishizu A; Honda H; Kataoka K; Kumano K; Akiyama H; Sudo T; Kurokawa M; Suda T
    Blood; 2014 Apr; 123(16):2540-9. PubMed ID: 24574458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
    Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R
    PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
    Kikuchi S; Nagai T; Kunitama M; Kirito K; Ozawa K; Komatsu N
    Cancer Sci; 2007 Dec; 98(12):1949-58. PubMed ID: 17900262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
    Carter BZ; Mak DH; Cortes J; Andreeff M
    Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H; Holyoake TL; Bhatia R
    Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.